H. Lundbeck A/S (Lundbeck) announced that Dr. Sandbrink will join Lundbeck on 1 January 2022 as Senior Vice President, Head of Clinical Development. Dr. Sandbrink will play a vital role in advancing Lundbeck's clinical pipeline towards providing transformative medicines for people living with niche and rare brain diseases. Dr. Sandbrink is a highly accomplished Clinical Development leader in both larger pharmaceutical companies as well as small biotechnology entities. He brings more than 20 years of experience spanning all stages of clinical development, from First-in-Human and translational/experimental medicine studies to pivotal trials, regulatory submissions and product launches, including Medical Affairs, Regulatory Affairs and Pharmacovigilance.